Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery 35% Improvement Relative Risk c19early.org/k Gutiérrez-Castrellón et al. NCT04517422 Probiotics RCT EARLY Is early treatment with probiotics beneficial for COVID-19? Double-blind RCT 293 patients in Mexico Improved recovery with probiotics (p=0.000017) Gutiérrez-Castrellón et al., Gut Microbes, doi:10.1080/19490976.2021.2018899 Favors probiotics Favors control
Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial
Gutiérrez-Castrellón et al., Gut Microbes, doi:10.1080/19490976.2021.2018899 (date from earlier preprint), NCT04517422 (history)
Gutiérrez-Castrellón et al., Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded,.., Gut Microbes, doi:10.1080/19490976.2021.2018899 (date from earlier preprint), NCT04517422
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 293 outpatients in Mexico, 147 treated with a probiotic composed of three L. plantarum strains (KABP022, KABP023 and KABP033) and one P. acidilacti strain (KABP021), showing improved recovery with treatment. There were no hospitalizations or deaths. NCT04517422 (history).
The immune effects of probiotics are strain-specific.
risk of no recovery, 34.7% lower, RR 0.65, p < 0.001, treatment 69 of 147 (46.9%), control 105 of 146 (71.9%), NNT 4.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gutiérrez-Castrellón et al., 24 May 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, peer-reviewed, 9 authors, average treatment delay 4.0 days, trial NCT04517422 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: Gut Microbes ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/kgmi20 Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial Pedro Gutiérrez-Castrellón, Tania Gandara-Martí, Ana T. Abreu Y Abreu, Cesar D. Nieto-Rufino, Eduardo López-Orduña, Irma Jiménez-Escobar, Carlos Jiménez-Gutiérrez, Gabriel López-Velazquez & Jordi Espadaler-Mazo To cite this article: Pedro Gutiérrez-Castrellón, Tania Gandara-Martí, Ana T. Abreu Y Abreu, Cesar D. Nieto-Rufino, Eduardo López-Orduña, Irma Jiménez-Escobar, Carlos Jiménez-Gutiérrez, Gabriel López-Velazquez & Jordi Espadaler-Mazo (2022) Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial, Gut Microbes, 14:1, 2018899, DOI: 10.1080/19490976.2021.2018899 To link to this article: https://doi.org/10.1080/19490976.2021.2018899 © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. View supplementary material Published online: 11 Jan 2022. Submit your article to this journal Article views: 7027 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=kgmi20 GUT MICROBES 2022, VOL. 14, NO. 1, e2018899 (16 pages) https://doi.org/10.1080/19490976.2021.2018899 RESEARCH PAPER Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial Pedro Gutiérrez-Castrellón a,b, Tania Gandara-Martía, Ana T. Abreu Y Abreuc, Cesar D. Nieto-Rufinoa, Eduardo López-Orduñad, Irma Jiménez-Escobara, Carlos Jiménez-Gutiérreza, Gabriel López-Velazquezb, and Jordi Espadaler-Mazo e a Centro de Investigación Translacional en Ciencias de la Salud, Hospital General Dr. Manuel Gea Gonzalez, Ciudad de México, (CDMX), México; International Scientific Council for Probiotics, Ciudad de México, (CDMX), México; cDigestive Unit, Hospital Angeles Pedregal, Ciudad de México, (CDMX), México; dDiagnoMol SA de CV, Ciudad de México (CDMX), México; eR&D Department, AB-Biotics SA (KANEKA Group) Sant Cugat, (Barcelona) Spain b ABSTRACT ARTICLE HISTORY Intestinal bacteria may influence lung homeostasis via the gut-lung axis. We conducted a singlecenter, quadruple-blinded, randomized trial in adult symptomatic Coronavirus Disease 2019 (Covid19) outpatients. Subjects were allocated 1:1 to probiotic formula (strains Lactiplantibacillus plantarum KABP022, KABP023, and KAPB033, plus strain Pediococcus acidilactici KABP021, totaling 2 × 109 colony-forming units (CFU)) or placebo, for 30 days. Co-primary endpoints included: i) proportion of patients in complete symptomatic and viral remission; ii) proportion progressing to moderate or severe disease with hospitalization, or death; and iii) days on Intensive Care Unit (ICU). Three hundred subjects were randomized (median age 37.0 years [range 18 to 60], 161 [53.7%] women, 126 [42.0%] having known metabolic risk factors), and 293 completed the study (97.7%). Complete remission was achieved by 78 of 147 (53.1%) in probiotic group compared to 41 of 146 (28.1%) in placebo (RR: 1.89 [95 CI 1.40–2.55]; P < .001), significant after multiplicity correction. No hospitalizations or deaths occurred during the study, precluding the assessment of remaining coprimary outcomes. Probiotic supplementation was well-tolerated and reduced..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit